The literature has underlined an association between HER2 activating mutations in colorectal cancer and resistance to therapy. While these mutations reduce the efficacy of EGFR antibody agents such as cetuximab the tumors remain responsive to dual HER2 targeted therapy with tyrosine kinase inhibitors like neratinib(1). Additionally, while we detect activating mutations in about 7% of […]